Antiviral Drugs - Indonesia

Indonesia

Indonesia is projected to witness a significant increase in revenue within the Antiviral Drugs market.
By 2024, the projected revenue is estimated to reach US$127.30m.
This growth is expected to continue with an annual growth rate (CAGR 2024-2029) of 2.34%.
Consequently, the market volume is projected to reach US$142.90m by 2029.
In comparison to other countries worldwide, United States is anticipated to generate the highest revenue, with an estimated amount of US$30,640.00m in 2024.
Indonesia's antiviral drug market is witnessing a surge in demand due to the country's tropical climate and high prevalence of viral infections.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Antiviral Drugs in Indonesia has been on the rise in recent years.

Customer preferences: Indonesian customers have shown a preference for Antiviral Drugs due to the increasing prevalence of viral diseases in the country. The outbreak of diseases such as dengue fever, influenza, and Zika virus has contributed to the growing demand for Antiviral Drugs in the country.

Trends in the market: The Antiviral Drugs market in Indonesia has witnessed a significant growth in recent years. The market has been driven by the increasing prevalence of viral diseases in the country. The demand for Antiviral Drugs is expected to continue to rise in the future due to the growing awareness of the benefits of these drugs in treating viral diseases.

Local special circumstances: Indonesia is the world's fourth most populous country, and its population is expected to continue to grow in the future. The growing population is expected to contribute to the increasing demand for Antiviral Drugs in the country. Additionally, Indonesia is a tropical country, which makes it more susceptible to the outbreak of viral diseases.

Underlying macroeconomic factors: The Indonesian government has been investing heavily in the healthcare sector in recent years. The government's efforts to improve healthcare infrastructure and increase access to healthcare services have contributed to the growth of the Antiviral Drugs market in the country. Additionally, the growing middle class in Indonesia has contributed to the increasing demand for healthcare services, including Antiviral Drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.